echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Safety will be the focus of research and development of the new crown vaccine, according to a rare statement from nine major U.S. and European pharmaceutical companies.

    Safety will be the focus of research and development of the new crown vaccine, according to a rare statement from nine major U.S. and European pharmaceutical companies.

    • Last Update: 2020-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 8, senior executives of nine major pharmaceutical companies in the U.S. and Europe issued a rare joint statement saying they would not apply for approval from the relevant authorities until the vaccine had passed phase III clinical trials and was proven to be safe and effective, the U.S. daily reported.
    said the move would help boost public confidence in the vaccine.
    "We believe this statement will help ensure public trust in rigorous scientific and regulatory processes in which the new crown vaccine will be evaluated and may eventually be approved," nine pharmaceutical executives reportedly wrote in a joint statement.
    executives also vowed to "apply for approval or emergency use permits only after Phase III clinical trials have confirmed that the vaccine is safe and effective, and that the trials were designed and implemented to meet the conditions set by professional authorities such as the U.S. Food and Drug Administration."
    they also vowed to "always put the safety and health of vaccinators first."
    said in the "historic statement" that the companies would "maintain the integrity of the scientific process when it is possible to apply to global authorities for approval for the first new crown vaccine at a later time,"
    reported.
    The statement also does not rule out the use of some data from large-scale Phase III vaccine trials to apply for emergency use permits;
    said the drug company executives who signed the statement were Pfizer, Johnson and Johnson, Moderna, Novavax, GlaxoSmithKline, AstraZeneca, Merck, BioNTech and Sanofi, France.
    comes after the U.S. Centers for Disease Control and Prevention (CDC) asked states to have the equipment they need to distribute vaccines by November 1.
    , U.S. infectious disease expert Fuchs said on September 8th that the new vaccine may not be available before the U.S. election.
    said at a conference that vaccines were more likely to be successful by the end of the year, but that "there can be no decisive answer" until November 3.
    U.S. President Donald Trump said at a news conference Wednesday that the vaccine is expected to be distributed before polling day in the U.S. election.
    U.S. infectious disease experts and scientists are concerned that the vaccine approval process could be "politically" affected.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.